GBLX — GB Sciences Income Statement
0.000.00%
Last trade - 00:00- $3.15m
- $4.64m
Annual income statement for GB Sciences, fiscal year end - March 31st, USD millions except per share, conversion factor applied.
R2019 March 31st | R2020 March 31st | 2021 March 31st | 2022 March 31st | 2023 March 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 3.45 | 0 | 0 | 0 | 0 |
| Cost of Revenue | |||||
| Gross Profit | 0.208 | 0 | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 16.6 | 3.46 | 1.53 | -0.335 | 4.05 |
| Operating Profit | -13.2 | -3.46 | -1.53 | 0.335 | -4.05 |
| Gain / Loss on Sale of Assets | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -21.5 | -4.75 | -3.33 | -0.147 | -4.13 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -22 | -4.75 | -3.33 | -0.147 | -4.13 |
| Minority Interest | |||||
| Net Income Before Extraordinary Items | |||||
| Extraordinary Items | |||||
| Net Income | -23.7 | -12.4 | -3.73 | -0.531 | -4.13 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -23.7 | -12.4 | -3.73 | -0.531 | -4.13 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.1 | -0.024 | -0.013 | -0.007 | -0.005 |